berberine has been researched along with Hepatocellular Carcinoma in 62 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Recently, berberine (BBR) has been characterized as a modulator of PPARs; however, the matter of whether PPARs are involved in the inhibitory effect of BBR on hepatocellular carcinoma (HCC) is not well understood." | 8.31 | Berberine activates PPARδ and promotes gut microbiota-derived butyric acid to suppress hepatocellular carcinoma. ( Shaw, PC; Shou, JW, 2023) |
| "Hepatocellular carcinoma (HCC) can be produced from aflatoxin B1 (AFB1) administration." | 8.31 | Berberine-loaded albumin nanoparticles reverse aflatoxin B1-induced liver hyperplasia. ( Fathy, SA; Ghareeb, DA; Hamdy, GM; Khedr, SM, 2023) |
| "Berberine, an bioactive isoquinolin alkaloid from traditional Chinese herbs, is considered to be a promising agent based on its remarkable activity against hepatocellular carcinoma." | 7.85 | Berberine-loaded Janus nanocarriers for magnetic field-enhanced therapy against hepatocellular carcinoma. ( Chang, ZM; Chen, L; Dong, WF; Li, J; Li, L; Li, M; Lu, MM; Shao, D; Wang, YS; Wang, Z; Zhang, Y; Zheng, X, 2017) |
| " In the present study, the inhibitory effect of BBR on hepatocellular carcinoma (HCC) via the suppression of the arachidonic acid (AA) metabolic pathway was investigated." | 7.81 | Berberine induces apoptosis by suppressing the arachidonic acid metabolic pathway in hepatocellular carcinoma. ( Chen, L; Kan, M; Li, J; Li, O; Liu, S; Pan, Y; Shao, D; Zhang, M; Zhang, X; Zheng, H, 2015) |
| "To investigate the involvement of p53 in the regulatory network of microRNA-23a (miR-23a) in berberine-treated hepatocellular carcinoma (HCC) cells." | 7.80 | Berberine-induced tumor suppressor p53 up-regulation gets involved in the regulatory network of MIR-23a in hepatocellular carcinoma. ( Feng, Y; Tan, HY; Tsao, SW; Wang, N; Wang, X; Zhu, M, 2014) |
| "Berberine (BBR) is a natural compound derived from some medicinal plants, and accumulating evidence has shown its potent anti-tumor activity with diverse action on tumor cells, including inducing cancer cell death and blocking cell cycle and migration." | 5.43 | Up-Regulation of PAI-1 and Down-Regulation of uPA Are Involved in Suppression of Invasiveness and Motility of Hepatocellular Carcinoma Cells by a Natural Compound Berberine. ( Cao, F; Feng, Y; Li, H; Liu, M; Tan, Y; Wang, N; Wang, X; Xiang, L; Yu, X; Zhang, J, 2016) |
| "Berberine could suppress the transcription level of Id-1 through inhibiting its promotor activity." | 5.42 | Berberine suppresses Id-1 expression and inhibits the growth and development of lung metastases in hepatocellular carcinoma. ( Cheung, KC; Cheung, YC; Feng, Y; Lui, VW; Man, K; Tsang, CM; Tsao, SW, 2015) |
| "Pretreatment with berberine in HepG2 cells resulted in a significant increase in phosphorylated AMP‑activated protein kinase (AMPK), as well as a marked elevation in phosphorylated Akt levels." | 5.39 | Berberine induces selective apoptosis through the AMPK‑mediated mitochondrial/caspase pathway in hepatocellular carcinoma. ( Huang, N; Yang, X, 2013) |
| "Berbamine treatment decreased the cell growth in a dose-dependent manner with an IC(50) value of 34." | 5.35 | Berbamine induces Fas-mediated apoptosis in human hepatocellular carcinoma HepG2 cells and inhibits its tumor growth in nude mice. ( Dong, Q; Dong, QH; Lv, QH; Wang, GY; Xu, RZ, 2009) |
| " Recently, berberine (BBR) has been characterized as a modulator of PPARs; however, the matter of whether PPARs are involved in the inhibitory effect of BBR on hepatocellular carcinoma (HCC) is not well understood." | 4.31 | Berberine activates PPARδ and promotes gut microbiota-derived butyric acid to suppress hepatocellular carcinoma. ( Shaw, PC; Shou, JW, 2023) |
| "Hepatocellular carcinoma (HCC) can be produced from aflatoxin B1 (AFB1) administration." | 4.31 | Berberine-loaded albumin nanoparticles reverse aflatoxin B1-induced liver hyperplasia. ( Fathy, SA; Ghareeb, DA; Hamdy, GM; Khedr, SM, 2023) |
| "Sorafenib resistance is one of the major factors affecting the prognosis of patients with hepatocellular carcinoma (HCC)." | 3.88 | Berberine, a natural plant alkaloid, synergistically sensitizes human liver cancer cells to sorafenib. ( Gu, C; Huang, Y; Liu, S; Mai, W; Nie, Y; Wang, K; Yang, H; Yu, G; Zhao, D; Zhong, Y, 2018) |
| " Herein, we propose dual-functionalized spray-dried casein micelles (CAS-MCs) for combined delivery of two phytochemicals; berberine (BRB) and diosmin (DSN) as targeted therapy of hepatocellular carcinoma (HCC)." | 3.88 | Dual-targeted casein micelles as green nanomedicine for synergistic phytotherapy of hepatocellular carcinoma. ( Abdelmoneem, MA; Elkhodairy, KA; Elzoghby, AO; Fang, JY; Helmy, MW; Mahmoud, M; Sallam, M; Zaky, A, 2018) |
| "Berberine, an bioactive isoquinolin alkaloid from traditional Chinese herbs, is considered to be a promising agent based on its remarkable activity against hepatocellular carcinoma." | 3.85 | Berberine-loaded Janus nanocarriers for magnetic field-enhanced therapy against hepatocellular carcinoma. ( Chang, ZM; Chen, L; Dong, WF; Li, J; Li, L; Li, M; Lu, MM; Shao, D; Wang, YS; Wang, Z; Zhang, Y; Zheng, X, 2017) |
| " In the present study, the inhibitory effect of BBR on hepatocellular carcinoma (HCC) via the suppression of the arachidonic acid (AA) metabolic pathway was investigated." | 3.81 | Berberine induces apoptosis by suppressing the arachidonic acid metabolic pathway in hepatocellular carcinoma. ( Chen, L; Kan, M; Li, J; Li, O; Liu, S; Pan, Y; Shao, D; Zhang, M; Zhang, X; Zheng, H, 2015) |
| "To investigate the involvement of p53 in the regulatory network of microRNA-23a (miR-23a) in berberine-treated hepatocellular carcinoma (HCC) cells." | 3.80 | Berberine-induced tumor suppressor p53 up-regulation gets involved in the regulatory network of MIR-23a in hepatocellular carcinoma. ( Feng, Y; Tan, HY; Tsao, SW; Wang, N; Wang, X; Zhu, M, 2014) |
| " In the present study, we investigated the anti-carcinogenic effects of Coptis chinensis and its major constituent, berberine, in HepG2 hepatocellular carcinoma (HCC) cells and attempted to elucidate the underlying mechanism, including involvement of the nonsteroidal anti-inflammatory drug (NSAID)-activated gene (NAG-1)." | 3.75 | Coptis chinensis inhibits hepatocellular carcinoma cell growth through nonsteroidal anti-inflammatory drug-activated gene activation. ( Auyeung, KK; Ko, JK, 2009) |
| "In conclusion, p53 status in human hepatocellular cancer cell lines modulates responses to plant-derived therapies." | 1.72 | Hepatocellular cancer cell lines, Hep-3B and Hep-G2 display the pleiotropic response to resveratrol and berberine. ( Adamiec-Organisciok, M; Dziedzic, A; Filipec-Kanizaj, T; Grgurevic, I; Hudy, D; Jagodzinski, M; Kukla, M; Los, L; Nackiewicz, J; Skladany, L; Skonieczna, M, 2022) |
| "Berberine (BBR) has been previously reported to inhibit hepatoma cell growth, but the main type of cell death elicited by BBR, and whether the alkaloid can inhibit hepatoma cells carrying HCV genomes, is unclear." | 1.56 | Targeting Autophagy Augments BBR-Mediated Cell Death in Human Hepatoma Cells Harboring Hepatitis C Virus RNA. ( Jassey, A; Lin, LT; Liu, CH; Richardson, CD; Tai, CJ; Wong, SH, 2020) |
| "Berberine promotes endocytosis of activated EGFR, while as Costunolide increases ubiquitination of EGFR and reduces EGFR recycling to cell membrane distribution, thereby inhibiting EGF signaling." | 1.56 | DaHuangWan targets EGF signaling to inhibit the proliferation of hepatoma cells. ( Burenbatu, B; Feng, Q; Genna, B; Si, H; Wang, H; Wang, J; Zhuang, X, 2020) |
| "However, in hepatoma cells like HepG2, the expressions of uptake transporters are minimal but efflux transporters are relatively high." | 1.51 | Mitochondrial membrane potential played crucial roles in the accumulation of berberine in HepG2 cells. ( Li, Q; Lin, G; Liu, C; Ma, BL; Ma, YM; Wang, XY; Wu, F; Zhang, JQ; Zhou, T, 2019) |
| "Radiation therapy is a major treatment in hepatocellular carcinoma (HCC)." | 1.51 | Berberine enhances the radiosensitivity of hepatoma cells by Nrf2 pathway. ( Cao, X; Lin, Y; You, X, 2019) |
| "Berberine is an isoquinoline alkaloid extracted from Rhizoma coptidis and shows anti-hyperlipidemia effect in vivo and in vitro." | 1.48 | 9-O-benzoyl-substituted berberine exerts a triglyceride-lowering effect through AMPK signaling pathway in human hepatoma HepG2 cells. ( Cao, S; Cheng, L; Deng, Y; Kang, N; Qiu, F; Yan, J; Yu, S; Zhu, Y, 2018) |
| "A human hepatoma xenograft model was established by intrahepatic injection of HepG2 cells containing nuclear factor-κB-driven luciferase genes in immunocompetent mice." | 1.46 | Exploration of anti-cancer effects and mechanisms of Zuo-Jin-Wan and its alkaloid components in vitro and in orthotopic HepG2 xenograft immunocompetent mice. ( Chiang, SY; Chou, ST; Ho, TY; Hsiang, CY; Hsieh, CL; Huang, HF; Lai, MT; Lo, HY, 2017) |
| "Berberine (BBR) is a natural compound derived from some medicinal plants, and accumulating evidence has shown its potent anti-tumor activity with diverse action on tumor cells, including inducing cancer cell death and blocking cell cycle and migration." | 1.43 | Up-Regulation of PAI-1 and Down-Regulation of uPA Are Involved in Suppression of Invasiveness and Motility of Hepatocellular Carcinoma Cells by a Natural Compound Berberine. ( Cao, F; Feng, Y; Li, H; Liu, M; Tan, Y; Wang, N; Wang, X; Xiang, L; Yu, X; Zhang, J, 2016) |
| "Berberine is an ancient multipotent alkaloid drug which derived from Coptis chinensis plants." | 1.43 | Antiproliferation of berberine is mediated by epigenetic modification of constitutive androstane receptor (CAR) metabolic pathway in hepatoma cells. ( Jia, YR; Li, P; Lu, C; Miao, XJ; Pan, HH; Ren, H; Wang, HB; Wang, X; Yuan, L; Zhang, GL; Zhang, L, 2016) |
| "Berberine could suppress the transcription level of Id-1 through inhibiting its promotor activity." | 1.42 | Berberine suppresses Id-1 expression and inhibits the growth and development of lung metastases in hepatocellular carcinoma. ( Cheung, KC; Cheung, YC; Feng, Y; Lui, VW; Man, K; Tsang, CM; Tsao, SW, 2015) |
| "Berberine has been identified with anti-proliferative effects on various cancer cells." | 1.42 | Functional Cross-Talking between Differentially Expressed and Alternatively Spliced Genes in Human Liver Cancer Cells Treated with Berberine. ( Cao, Z; Jiao, N; Ma, C; Sheng, Z; Sun, Y; Tang, K; Zhu, R, 2015) |
| "Berberine is an isoquinoline alkaloid isolated from medicinal plant species, which has been used in traditional Chinese medicine with no significant side effects." | 1.40 | Berberine sensitizes rapamycin‑mediated human hepatoma cell death in vitro. ( Chen, Y; Gao, X; Gou, X; Guo, N; He, X; Hu, Z; Mi, M; Tang, X; Yan, A, 2014) |
| "Berberine (BBR) is an isoquinoline alkaloid isolated from several Chinese herbal medicines, such as Coptis chinensis, Berberis aristata, and Coptis japonica." | 1.40 | Berberine metabolites could induce low density lipoprotein receptor up-regulation to exert lipid-lowering effects in human hepatoma cells. ( Bin, W; Cao, S; Kang, N; Qiu, F; Wang, Y; Xu, P; Yan, J; Zhou, Y, 2014) |
| "Pretreatment with berberine in HepG2 cells resulted in a significant increase in phosphorylated AMP‑activated protein kinase (AMPK), as well as a marked elevation in phosphorylated Akt levels." | 1.39 | Berberine induces selective apoptosis through the AMPK‑mediated mitochondrial/caspase pathway in hepatocellular carcinoma. ( Huang, N; Yang, X, 2013) |
| "Current chemotherapeutic strategies for liver cancer have limitations." | 1.39 | Berberine induces apoptosis via the mitochondrial pathway in liver cancer cells. ( Ho, WS; Yip, NK, 2013) |
| "Zuo-Jin-Wan (ZJW) has been used to treat hepatocellular carcinoma in Asia." | 1.37 | Inhibitory effects of Zuo-Jin-Wan and its alkaloidal ingredients on activator protein 1, nuclear factor-κB, and cellular transformation in HepG2 cells. ( Chang, CS; Chao, DC; Ho, TY; Hsiang, CY; Huang, HC; Kao, ST; Liang, JA; Lin, LJ; Wu, SL, 2011) |
| "Berbamine treatment decreased the cell growth in a dose-dependent manner with an IC(50) value of 34." | 1.35 | Berbamine induces Fas-mediated apoptosis in human hepatocellular carcinoma HepG2 cells and inhibits its tumor growth in nude mice. ( Dong, Q; Dong, QH; Lv, QH; Wang, GY; Xu, RZ, 2009) |
| "Human and murine hepatoma cells were treated with berberine (0." | 1.30 | Up-regulation of multidrug resistance transporter expression by berberine in human and murine hepatoma cells. ( Chi, CW; Lin, HL; Liu, TY; Lui, WY, 1999) |
| "Berberine was shown to inhibit AP-1 activity in a dose- and time-dependent manner at concentrations higher than 0." | 1.30 | Inhibition of activator protein 1 activity by berberine in human hepatoma cells. ( Akao, S; Fujiwara, H; Fukuda, K; Hibiya, Y; Koshiji, M; Mutoh, M, 1999) |
| "Berberine is an alkaloid found in many plants, including the Coptis chinensis and Arcangelisia flava." | 1.29 | Flowcytometric analysis of the effect of berberine on the expression of glucocorticoid receptors in human hepatoma HepG2 cells. ( Chang, YF; Chao, TW; Chi, CW; Chiang, SH; Liu, TY; Lui, WY; P'eng, FK, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (4.84) | 18.2507 |
| 2000's | 6 (9.68) | 29.6817 |
| 2010's | 42 (67.74) | 24.3611 |
| 2020's | 11 (17.74) | 2.80 |
| Authors | Studies |
|---|---|
| D'Arcy, MS | 1 |
| Pike, CVS | 1 |
| Coussons, PJ | 1 |
| Skonieczna, M | 1 |
| Adamiec-Organisciok, M | 1 |
| Hudy, D | 1 |
| Dziedzic, A | 1 |
| Los, L | 1 |
| Skladany, L | 1 |
| Grgurevic, I | 1 |
| Filipec-Kanizaj, T | 1 |
| Jagodzinski, M | 1 |
| Kukla, M | 1 |
| Nackiewicz, J | 1 |
| Cheng, CS | 1 |
| Tan, HY | 4 |
| Zhang, C | 1 |
| Chan, YT | 1 |
| Zhang, ZJ | 1 |
| Man, K | 2 |
| Yuen, MF | 1 |
| Wang, N | 5 |
| Feng, Y | 6 |
| Lin, X | 1 |
| Chen, J | 1 |
| Li, X | 1 |
| Chen, D | 1 |
| Luo, K | 1 |
| Deng, Y | 2 |
| Yang, D | 1 |
| Huang, Z | 1 |
| Tao, C | 1 |
| Shou, JW | 1 |
| Shaw, PC | 1 |
| Khedr, SM | 1 |
| Ghareeb, DA | 1 |
| Fathy, SA | 1 |
| Hamdy, GM | 1 |
| Song, L | 1 |
| Luo, Y | 1 |
| Wang, X | 5 |
| Almutairi, MM | 1 |
| Pan, H | 1 |
| Li, W | 1 |
| Liu, Y | 1 |
| Wang, Q | 1 |
| Hong, M | 2 |
| Zhang, F | 2 |
| Jia, Y | 1 |
| Zheng, X | 2 |
| Shao, D | 3 |
| Zhao, Y | 2 |
| Wang, Z | 4 |
| Dawulieti, J | 1 |
| Liu, W | 1 |
| Sun, M | 1 |
| Sun, W | 1 |
| Pan, Y | 2 |
| Cui, L | 1 |
| Wang, Y | 3 |
| He, K | 1 |
| Zhang, M | 3 |
| Li, J | 4 |
| Dong, WF | 2 |
| Chen, L | 3 |
| Tai, CJ | 2 |
| Jassey, A | 1 |
| Liu, CH | 1 |
| Richardson, CD | 1 |
| Wong, SH | 1 |
| Lin, LT | 1 |
| Si, H | 1 |
| Genna, B | 1 |
| Zhuang, X | 1 |
| Wang, J | 1 |
| Burenbatu, B | 1 |
| Feng, Q | 2 |
| Wang, H | 2 |
| Kim, SY | 2 |
| Hwangbo, H | 2 |
| Lee, H | 2 |
| Park, C | 1 |
| Kim, GY | 2 |
| Moon, SK | 1 |
| Yun, SJ | 1 |
| Kim, WJ | 1 |
| Cheong, J | 2 |
| Choi, YH | 2 |
| Ramesh, G | 1 |
| Das, S | 1 |
| Bola Sadashiva, SR | 1 |
| Kim, MY | 1 |
| Ji, SY | 1 |
| Kwon, CY | 1 |
| Leem, SH | 1 |
| Hong, SH | 1 |
| Sun, Y | 2 |
| Yuan, X | 1 |
| Han, Y | 1 |
| Chang, X | 1 |
| Xu, X | 1 |
| Li, Y | 3 |
| Gao, X | 2 |
| Saxena, S | 1 |
| Shukla, S | 2 |
| Kakkar, P | 2 |
| Hu, WQ | 1 |
| Wang, W | 2 |
| Fang, DL | 1 |
| Yin, XF | 1 |
| Huang, Y | 1 |
| Wang, K | 1 |
| Gu, C | 1 |
| Yu, G | 1 |
| Zhao, D | 1 |
| Mai, W | 1 |
| Zhong, Y | 1 |
| Liu, S | 2 |
| Nie, Y | 1 |
| Yang, H | 1 |
| Abdelmoneem, MA | 1 |
| Mahmoud, M | 1 |
| Zaky, A | 1 |
| Helmy, MW | 1 |
| Sallam, M | 1 |
| Fang, JY | 1 |
| Elkhodairy, KA | 1 |
| Elzoghby, AO | 1 |
| Cao, S | 2 |
| Yu, S | 1 |
| Cheng, L | 1 |
| Yan, J | 2 |
| Zhu, Y | 1 |
| Qiu, F | 2 |
| Kang, N | 2 |
| Dai, B | 1 |
| Ma, Y | 1 |
| Yang, T | 1 |
| Fan, M | 1 |
| Yu, R | 1 |
| Su, Q | 1 |
| Liu, F | 1 |
| Yang, C | 1 |
| Zhang, Y | 3 |
| Li, Q | 2 |
| Zhou, T | 1 |
| Liu, C | 1 |
| Wang, XY | 1 |
| Zhang, JQ | 1 |
| Wu, F | 1 |
| Lin, G | 1 |
| Ma, YM | 1 |
| Ma, BL | 1 |
| You, X | 1 |
| Cao, X | 1 |
| Lin, Y | 1 |
| Zhang, L | 4 |
| Zu, Y | 1 |
| Liu, T | 1 |
| Zhang, B | 2 |
| He, W | 1 |
| Yang, X | 1 |
| Huang, N | 1 |
| Yip, NK | 1 |
| Ho, WS | 1 |
| Sengupta, D | 1 |
| Chowdhury, KD | 1 |
| Sarkar, A | 1 |
| Paul, S | 1 |
| Sadhukhan, GC | 1 |
| Lo, TF | 1 |
| Tsai, WC | 2 |
| Chen, ST | 1 |
| Wang, L | 1 |
| Wei, D | 1 |
| Han, X | 2 |
| Zhang, W | 3 |
| Fan, C | 1 |
| Zhang, J | 2 |
| Mo, C | 1 |
| Yang, M | 1 |
| Zhou, Q | 1 |
| Xiao, H | 1 |
| Zhou, Y | 2 |
| Xu, P | 1 |
| Bin, W | 1 |
| Zhu, M | 1 |
| Tsao, SW | 3 |
| Rizvi, F | 1 |
| Raisuddin, S | 1 |
| Guo, N | 1 |
| Yan, A | 1 |
| Chen, Y | 1 |
| He, X | 1 |
| Hu, Z | 1 |
| Mi, M | 1 |
| Tang, X | 2 |
| Gou, X | 2 |
| Ting, CT | 1 |
| Li, WC | 2 |
| Chen, CY | 1 |
| Tsai, TH | 1 |
| Tsang, CM | 2 |
| Cheung, KC | 1 |
| Cheung, YC | 1 |
| Lui, VW | 1 |
| Cheung, F | 1 |
| Lao, L | 1 |
| Nagamatsu, T | 1 |
| Li, O | 1 |
| Kan, M | 1 |
| Zheng, H | 1 |
| Zhang, X | 1 |
| Zhao, W | 1 |
| Jiang, G | 1 |
| Bi, C | 1 |
| Liu, J | 2 |
| Ye, C | 1 |
| He, H | 1 |
| Li, L | 2 |
| Song, D | 1 |
| Shao, R | 1 |
| Sheng, Z | 1 |
| Zhu, R | 1 |
| Jiao, N | 1 |
| Tang, K | 1 |
| Cao, Z | 1 |
| Ma, C | 1 |
| Hou, J | 1 |
| Mi, P | 1 |
| Mao, L | 1 |
| Xu, L | 1 |
| Xiao, L | 1 |
| Cao, H | 1 |
| Song, G | 1 |
| Hu, T | 1 |
| Zhan, YY | 1 |
| Li, H | 2 |
| Liu, M | 1 |
| Cao, F | 1 |
| Yu, X | 1 |
| Tan, Y | 1 |
| Xiang, L | 1 |
| Miao, XJ | 1 |
| Pan, HH | 1 |
| Li, P | 1 |
| Ren, H | 1 |
| Jia, YR | 1 |
| Lu, C | 1 |
| Wang, HB | 1 |
| Yuan, L | 1 |
| Zhang, GL | 1 |
| Wang, YS | 1 |
| Chang, ZM | 1 |
| Lu, MM | 1 |
| Li, M | 2 |
| Chu, Q | 1 |
| Jiang, Y | 1 |
| Xu, C | 1 |
| Du, W | 1 |
| Tuguzbaeva, G | 1 |
| Qin, Y | 1 |
| Li, A | 1 |
| Sun, G | 1 |
| Cai, Y | 1 |
| Li, G | 1 |
| Du, Z | 1 |
| Bai, Y | 1 |
| Yang, B | 1 |
| Li, S | 1 |
| La, X | 1 |
| Li, Z | 1 |
| Yang, P | 1 |
| Chou, ST | 1 |
| Hsiang, CY | 2 |
| Lo, HY | 1 |
| Huang, HF | 1 |
| Lai, MT | 1 |
| Hsieh, CL | 1 |
| Chiang, SY | 1 |
| Ho, TY | 2 |
| Zhang, ZL | 1 |
| Liu, N | 1 |
| Han, XY | 1 |
| Liu, QC | 1 |
| Deng, WJ | 1 |
| Liao, CX | 1 |
| Wang, XN | 1 |
| Xu, LN | 1 |
| Yin, LH | 1 |
| Xu, YW | 1 |
| Qi, Y | 1 |
| Peng, JY | 1 |
| Wang, GY | 1 |
| Lv, QH | 1 |
| Dong, Q | 1 |
| Xu, RZ | 1 |
| Dong, QH | 1 |
| Hur, JM | 1 |
| Hyun, MS | 1 |
| Lim, SY | 1 |
| Lee, WY | 1 |
| Kim, D | 1 |
| Auyeung, KK | 1 |
| Ko, JK | 1 |
| Hao, CY | 1 |
| Jie, S | 1 |
| Tian, Y | 1 |
| Guo, D | 1 |
| Zhu, J | 1 |
| Gao, S | 1 |
| Jiang, L | 1 |
| Chao, DC | 1 |
| Lin, LJ | 1 |
| Kao, ST | 1 |
| Huang, HC | 1 |
| Chang, CS | 1 |
| Liang, JA | 1 |
| Wu, SL | 1 |
| Hou, Q | 1 |
| Liu, H | 1 |
| Tang, J | 1 |
| Yang, Y | 1 |
| Jing, X | 1 |
| Xiao, Q | 1 |
| Liu, B | 1 |
| Wang, G | 1 |
| Yang, J | 1 |
| Pan, X | 1 |
| Yang, Z | 1 |
| Zang, L | 1 |
| Lin, YC | 1 |
| Kuo, JY | 1 |
| Hsu, CC | 1 |
| Yu, MC | 1 |
| Wen, HW | 1 |
| Abidi, P | 1 |
| Jiang, JD | 1 |
| Lee, S | 1 |
| Lim, HJ | 1 |
| Park, JH | 1 |
| Lee, KS | 1 |
| Jang, Y | 1 |
| Park, HY | 1 |
| Chi, CW | 2 |
| Chang, YF | 1 |
| Chao, TW | 1 |
| Chiang, SH | 1 |
| P'eng, FK | 1 |
| Lui, WY | 2 |
| Liu, TY | 2 |
| Lin, HL | 1 |
| Fukuda, K | 1 |
| Hibiya, Y | 1 |
| Mutoh, M | 1 |
| Koshiji, M | 1 |
| Akao, S | 1 |
| Fujiwara, H | 1 |
1 review available for berberine and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Preventive and therapeutic role of traditional Chinese herbal medicine in hepatocellular carcinoma.
Topics: Abietanes; Benzylisoquinolines; Berberine; Carcinoma, Hepatocellular; Curcumin; Drugs, Chinese Herba | 2015 |
61 other studies available for berberine and Hepatocellular Carcinoma
| Article | Year |
|---|---|
A novel combined resveratrol/berberine phytochemotheraputic using the HePG2 cell line as a model for the treatment of hepatocarcinoma.
Topics: Apoptosis; Berberine; Carcinoma, Hepatocellular; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell P | 2021 |
Hepatocellular cancer cell lines, Hep-3B and Hep-G2 display the pleiotropic response to resveratrol and berberine.
Topics: Apoptosis; Berberine; Carcinoma, Hepatocellular; Cell Line; Cell Proliferation; Humans; Liver Neopla | 2022 |
Berberine suppresses metastasis and recurrence of hepatocellular carcinoma by targeting circulating tumour cells: abridged secondary publication.
Topics: Berberine; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Neoplasm Metastasis | 2022 |
Dimeric oxyberberine CT4-1 targets LINC02331 to induce cytotoxicity and inhibit chemoresistance via suppressing Wnt/β-catenin signaling in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Berberine; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor | 2023 |
Berberine activates PPARδ and promotes gut microbiota-derived butyric acid to suppress hepatocellular carcinoma.
Topics: Animals; bcl-2-Associated X Protein; Berberine; Butyric Acid; Carcinoma, Hepatocellular; Caspase 3; | 2023 |
Berberine-loaded albumin nanoparticles reverse aflatoxin B1-induced liver hyperplasia.
Topics: Aflatoxin B1; Albumins; Animals; Berberine; Carcinoma, Hepatocellular; Hyperplasia; Liver Neoplasms; | 2023 |
Exploring the active mechanism of berberine against HCC by systematic pharmacology and experimental validation.
Topics: Antineoplastic Agents; Apoptosis; Berberine; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movem | 2019 |
Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
Topics: Animals; Antineoplastic Agents; Apoptosis; Berberine; Carcinoma, Hepatocellular; Doxorubicin; Drug C | 2019 |
Targeting Autophagy Augments BBR-Mediated Cell Death in Human Hepatoma Cells Harboring Hepatitis C Virus RNA.
Topics: Autophagy; Berberine; Carcinoma, Hepatocellular; Cell Death; Cell Proliferation; Hepatitis C; Humans | 2020 |
DaHuangWan targets EGF signaling to inhibit the proliferation of hepatoma cells.
Topics: Apoptosis; Berberine; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; E | 2020 |
Induction of Apoptosis by Coptisine in Hep3B Hepatocellular Carcinoma Cells through Activation of the ROS-Mediated JNK Signaling Pathway.
Topics: Apoptosis; Berberine; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Humans; JNK Mitogen-Ac | 2020 |
Berberine, a natural alkaloid sensitizes human hepatocarcinoma to ionizing radiation by blocking autophagy and cell cycle arrest resulting in senescence.
Topics: Autophagy; Berberine; Carcinoma, Hepatocellular; Cell Proliferation; Cellular Senescence; G2 Phase C | 2020 |
Coptisine induces autophagic cell death through down-regulation of PI3K/Akt/mTOR signaling pathway and up-regulation of ROS-mediated mitochondrial dysfunction in hepatocellular carcinoma Hep3B cells.
Topics: Antineoplastic Agents; Autophagy; Berberine; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regul | 2021 |
Berberine ameliorates fatty acid-induced oxidative stress in human hepatoma cells.
Topics: Berberine; Carcinoma, Hepatocellular; Cell Line, Tumor; Diet, High-Fat; Fatty Acids; Hepatocytes; Hu | 2017 |
Berberine induced modulation of PHLPP2-Akt-MST1 kinase signaling is coupled with mitochondrial impairment and hepatoma cell death.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Bcl-2-Like | 2018 |
Identification of Biological Targets of Therapeutic Intervention for Hepatocellular Carcinoma by Integrated Bioinformatical Analysis.
Topics: Berberine; Carcinoma, Hepatocellular; Cell Line, Tumor; Computational Biology; Databases, Genetic; G | 2018 |
Berberine, a natural plant alkaloid, synergistically sensitizes human liver cancer cells to sorafenib.
Topics: Antineoplastic Agents; Apoptosis; Berberine; Carcinoma, Hepatocellular; Cell Proliferation; Drug Syn | 2018 |
Dual-targeted casein micelles as green nanomedicine for synergistic phytotherapy of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Berberine; Carcinoma, Hepatocellular; Caseins; Delayed-A | 2018 |
9-O-benzoyl-substituted berberine exerts a triglyceride-lowering effect through AMPK signaling pathway in human hepatoma HepG2 cells.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Berberine; Carcinoma, Hepatocellular; Fatty A | 2018 |
Synergistic effect of berberine and HMQ1611 impairs cell proliferation and migration by regulating Wnt signaling pathway in hepatocellular carcinoma.
Topics: Acetanilides; Animals; Benzamides; Berberine; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tu | 2019 |
Mitochondrial membrane potential played crucial roles in the accumulation of berberine in HepG2 cells.
Topics: Apoptosis; Berberine; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Carcinoma, Hepatocellular; Cell Cyc | 2019 |
Berberine enhances the radiosensitivity of hepatoma cells by Nrf2 pathway.
Topics: Animals; Apoptosis; Berberine; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Hep G2 Cells; | 2019 |
Generation of reactive oxygen species by a novel berberine-bile acid analog mediates apoptosis in hepatocarcinoma SMMC-7721 cells.
Topics: Acetylcysteine; Active Transport, Cell Nucleus; Antineoplastic Agents; Apoptosis; Apoptosis Inducing | 2013 |
Berberine induces selective apoptosis through the AMPK‑mediated mitochondrial/caspase pathway in hepatocellular carcinoma.
Topics: AMP-Activated Protein Kinases; Apoptosis; Berberine; Carcinoma, Hepatocellular; Caspases; Cell Line, | 2013 |
Berberine induces apoptosis via the mitochondrial pathway in liver cancer cells.
Topics: Apoptosis; Berberine; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Caspase Inhib | 2013 |
Berberine and S allyl cysteine mediated amelioration of DEN+CCl4 induced hepatocarcinoma.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Apoptosis; Berberine; Blotting, Western; Carbon T | 2014 |
MicroRNA-21-3p, a berberine-induced miRNA, directly down-regulates human methionine adenosyltransferases 2A and 2B and inhibits hepatoma cell growth.
Topics: Berberine; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA P | 2013 |
The combinational effect of vincristine and berberine on growth inhibition and apoptosis induction in hepatoma cells.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Berber | 2014 |
Berberine metabolites could induce low density lipoprotein receptor up-regulation to exert lipid-lowering effects in human hepatoma cells.
Topics: Berberine; Berberine Alkaloids; Berberis; Carcinoma, Hepatocellular; Coptis; Dose-Response Relations | 2014 |
Berberine-induced tumor suppressor p53 up-regulation gets involved in the regulatory network of MIR-23a in hepatocellular carcinoma.
Topics: Berberine; Carcinoma, Hepatocellular; Gene Regulatory Networks; Genes, p53; Hep G2 Cells; Humans; Li | 2014 |
FoxO proteins' nuclear retention and BH3-only protein Bim induction evoke mitochondrial dysfunction-mediated apoptosis in berberine-treated HepG2 cells.
Topics: Antioxidants; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Berberine; Blotting, | 2014 |
Berberine sensitizes rapamycin‑mediated human hepatoma cell death in vitro.
Topics: Berberine; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Drug Synergism; Hep G2 Cells; Hu | 2014 |
Berberine suppresses Id-1 expression and inhibits the growth and development of lung metastases in hepatocellular carcinoma.
Topics: Animals; Berberine; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Expression | 2015 |
Inhibition of eukaryotic elongation factor-2 confers to tumor suppression by a herbal formulation Huanglian-Jiedu decoction in human hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Berberine; Carcinoma, Hepatocellular; Cell Line, Tumor; Drugs, Chine | 2015 |
Berberine induces apoptosis by suppressing the arachidonic acid metabolic pathway in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Arachidonic Acid; Berberine; Carcinoma, Hepat | 2015 |
The dual topoisomerase inhibitor A35 preferentially and specially targets topoisomerase 2α by enhancing pre-strand and post-strand cleavage and inhibiting DNA religation.
Topics: Animals; Antigens, Neoplasm; Apoptosis; Berberine; Carcinoma, Hepatocellular; Cell Proliferation; Co | 2015 |
Functional Cross-Talking between Differentially Expressed and Alternatively Spliced Genes in Human Liver Cancer Cells Treated with Berberine.
Topics: Alternative Splicing; Antineoplastic Agents; Berberine; Carcinoma, Hepatocellular; Cell Line, Tumor; | 2015 |
Exo70 is transcriptionally up-regulated by hepatic nuclear factor 4α and contributes to cell cycle control in hepatoma cells.
Topics: Berberine; Carcinoma, Hepatocellular; CDC2 Protein Kinase; Cell Line, Tumor; Cyclin-Dependent Kinase | 2016 |
Up-Regulation of PAI-1 and Down-Regulation of uPA Are Involved in Suppression of Invasiveness and Motility of Hepatocellular Carcinoma Cells by a Natural Compound Berberine.
Topics: Anti-Inflammatory Agents; Berberine; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Dow | 2016 |
Antiproliferation of berberine is mediated by epigenetic modification of constitutive androstane receptor (CAR) metabolic pathway in hepatoma cells.
Topics: Antineoplastic Agents; Apoptosis; Berberine; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell | 2016 |
Berberine-loaded Janus nanocarriers for magnetic field-enhanced therapy against hepatocellular carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Berberine; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Carr | 2017 |
Pyroptosis is involved in the pathogenesis of human hepatocellular carcinoma.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antineoplastic Agents; Berberine; Carcinoma, Hepatocellula | 2016 |
Berberine Suppresses Cyclin D1 Expression through Proteasomal Degradation in Human Hepatoma Cells.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents, Phytogenic; Berberine; beta-Transduc | 2016 |
Berberine-induced autophagic cell death by elevating GRP78 levels in cancer cells.
Topics: Activating Transcription Factor 6; Apoptosis; Autophagy; Berberine; Biomarkers, Tumor; Carcinoma, He | 2017 |
Exploration of anti-cancer effects and mechanisms of Zuo-Jin-Wan and its alkaloid components in vitro and in orthotopic HepG2 xenograft immunocompetent mice.
Topics: Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Berberine; Carcinoma, Hepatocellular; Coptis; | 2017 |
Induction of Apoptosis by Berberine in Hepatocellular Carcinoma HepG2 Cells via Downregulation of NF-κB.
Topics: Apoptosis; Berberine; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dose-Response | 2017 |
Enhancement of apoptosis of human hepatocellular carcinoma SMMC-7721 cells through synergy of berberine and evodiamine.
Topics: Apoptosis; Berberine; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Drug Synergism; Human | 2008 |
Berbamine induces Fas-mediated apoptosis in human hepatocellular carcinoma HepG2 cells and inhibits its tumor growth in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Benzylisoquinolines; Berberine; Bisbenzimidaz | 2009 |
The combination of berberine and irradiation enhances anti-cancer effects via activation of p38 MAPK pathway and ROS generation in human hepatoma cells.
Topics: Acetylcysteine; Apoptosis; Berberine; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell S | 2009 |
Coptis chinensis inhibits hepatocellular carcinoma cell growth through nonsteroidal anti-inflammatory drug-activated gene activation.
Topics: Anticarcinogenic Agents; Berberine; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell L | 2009 |
Angiogenesis blockade as therapy for hepatocellular carcinoma: progress and challenges.
Topics: Angiogenesis Inhibitors; Animals; Berberine; Carcinoma, Hepatocellular; Down-Regulation; Endothelial | 2011 |
Berberine inhibits angiogenic potential of Hep G2 cell line through VEGF down-regulation in vitro.
Topics: Angiogenesis Inhibitors; Berberine; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Cu | 2011 |
Inhibitory effects of Zuo-Jin-Wan and its alkaloidal ingredients on activator protein 1, nuclear factor-κB, and cellular transformation in HepG2 cells.
Topics: Antineoplastic Agents, Phytogenic; Berberine; Carcinoma, Hepatocellular; Cell Transformation, Neopla | 2011 |
Berberine induces cell death in human hepatoma cells in vitro by downregulating CD147.
Topics: Apoptosis; Autophagy; Basigin; Berberine; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival | 2011 |
Berberine inhibits human hepatoma cell invasion without cytotoxicity in healthy hepatocytes.
Topics: Berberine; Blotting, Western; Carcinoma, Hepatocellular; Cell Line; Cell Survival; Hep G2 Cells; Hep | 2011 |
Optimizing manufacture of liposomal berberine with evaluation of its antihepatoma effects in a murine xenograft model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Berberine; Carcinoma, Hepatocellular; Caspase | 2013 |
Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine.
Topics: 3' Untranslated Regions; Berberine; Bile Acids and Salts; Carcinogens; Carcinoma, Hepatocellular; Ce | 2005 |
Berberine-induced LDLR up-regulation involves JNK pathway.
Topics: Anthracenes; Berberine; Carcinoma, Hepatocellular; Cell Line; Dose-Response Relationship, Drug; Gene | 2007 |
Flowcytometric analysis of the effect of berberine on the expression of glucocorticoid receptors in human hepatoma HepG2 cells.
Topics: alpha-Fetoproteins; Analysis of Variance; Berberine; Carcinoma, Hepatocellular; Cell Cycle; Cell Div | 1994 |
Up-regulation of multidrug resistance transporter expression by berberine in human and murine hepatoma cells.
Topics: Animals; Antineoplastic Agents, Hormonal; ATP Binding Cassette Transporter, Subfamily B, Member 1; B | 1999 |
Inhibition of activator protein 1 activity by berberine in human hepatoma cells.
Topics: Berberine; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Transcription Factor AP-1; Tumor Cell | 1999 |